The FDA approved Medtronic's next-generation CoreValve transcatheter aortic valve replacement (TAVR) device, the Evolut PRO valve, for severe, symptomatic aortic stenosis in patients at high or extreme risk for open surgery, the company announced Wednesday.
Medtronic cited 30-day clinical data from its 60-patient TAVR 2.0 Clinical Study, released last week at the American College of Cardiology meeting in Washington, D.C., showing a 1.7% mortality rate, 1.7% rate of disabling stroke, no severe paravalvular leak, 72.4% of patients with no more than trace leaks, and 11.8% requiring a new permanent pacemaker.
Whereas TAVR devices were the poster child for delayed device marketability, compared with in Europe, CoreValve Evolut PRO came first to the U.S.
market and is not approved elsewhere in the world.
The material on this site is for informational purposes only, and is not a substitute for medical advice, diagnosis or treatment provided by a qualified health care provider.© 2017 MedPage Today, LLC.